## Note
nid: 1495820898797
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::05_Pharm::22_Ruxolitinib, #AK_Step1_v11::#OME_banner::Basic_Science::13_Hematology_Oncology::18_Myeloproliferative_Disorders, #AK_Step1_v11::#Physeo::11_Pathology::10_HemeOnc_Pathology::14_Myeloproliferative_Disorders, #AK_Step1_v11::#SketchyPharm::08_Antineoplastics::SmallMoleculeInhibitors(TyrosineKinase_ProteasomeInhibitors_CDKInhibitors), #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::4-LowerYield
markdown: false

### Text
<div>
  <div>
    In patients taking <b>ruxolitinib</b>, an important side effect
    is {{c1::<b>hepato</b>}}<b>toxicity</b>
  </div>
</div>

### Extra
<i>Monitor LFT's in patients on this drug</i>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy
#REF!

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/heme-onc/myeloproliferative-disorders/acquire?ref=anki">
  <img src="_OME_AnkiFlashcards_Lesson_1.png"></a>
</div>

### Additional Resources


### One by one

